HBM Biopharma Summit 2026

27th - 29th September 2026

Park Hyatt Zurich
Registration

WELCOME

For more than a decade, HBM hosted yearly summits, providing a meeting platform for industry professionals and investors to exchange views with experts and peers about the latest developments in the biopharma industry. After the highly successful HBM Biopharma Summit 2025 we are delighted to announce the dates for the


HBM BIOPHARMA SUMMIT 2026


DATE & PLACE

27th - 29th September 2026

Park Hyatt Hotel Zurich, Switzerland


SPEAKERS

Jeffrey Berkowitz, Real Endpoints | Meenakshi Datta, Sidley Austin | Richard Francis, Teva | Richard Girling, Centerview Partners | Will Lewis, Insmed | Moncef Slaoui, Curevo Vaccine

PARTICIPANTS

List of participants PDF download


PRESENTING COMPANIES

Alumis | Arrakis | Biohaven | Cstone | Denali | Dren Bio | Electra Bio | Fangzhou | Karius | Mahzi | Numab | Nuvation Bio | Perspective | SOBI | SWIXX | Travere | Trevi | Zymeworks


NETWORKING

With networking being a key element of this event, we look forward to inspiring discussions and a lively exchange of views among all participants.

ACCOMMODATION

The Park Hyatt hotel offers a limited number of rooms during the conference at a reduced rate. These rooms are likely to sell your soon. Please book your room at the Park Hyatt Conference Booking Site

Other nearby hotels inlcude Hotel Motel 1, Baur au Lac, Hotel Alden Splügenschloss


DRESS CODE

Business casual (casual for dinners) throughout the conference.

CONFERENCE PROGRAM

REGISTRATION & WELCOME DESK

Ballroom Foyer

INFORMAL LUNCH AT PARK HYATT HOTEL

Mezzanine Foyer

UETLIBERG - ZURICH'S VERY OWN MOUNTAIN

At 871 metres (2,858 feet) above sea level, the Uetliberg towers over Zurich's rooftops. The Uetliberg Railway takes us almost to the top, leaving only a seven-minute walk through the forest to reach the summit and the Hotel Uto Kulm. From here, you can enjoy a fascinating 360° view. The hotel's own observation tower is the best viewing point. Enjoy a light apéritif while taking in the magnificent panoramic view of the city, the lake and the Alps.

LINDT CHOCO DELUXE PRIVATE TOUR

During this 90-minute guided tour, you will gain an insight into the production of cocoa and chocolate. You will learn how the Mayan 'cult' drink evolved into a European luxury and ultimately became accessible to all. In addition to the tasting stations in the exhibition and the tasting of creamy melting Lindor creations with a Maître Chocolatier, we are also offered the exclusive opportunity to taste ingredients and preliminary products of chocolate production. Finally, you can explore the world of chocolate in the 500 m² Lindt Chocolate Shop, where you will find the finest Swiss chocolate from Lindt, as well as a variety of sweet gift ideas.

TRANSFER TO DINNER LOCATION

Meet in Lobby

INFORMAL DINNER AT RESTAURANT SEEROSE

Restaurant Seerose

Seestrasse 493
8038 Zürich

GROUP TRANSFERS TO PARK HYATT HOTEL

Speakers

Jeffrey Berkowitz

CEO, Real Endpoints

Jeff Berkowitz is one of the rare executives whose career has spanned most key verticals in the global healthcare supply chain with executive committee and other senior roles at UnitedHealth Group, Walgreens Boots Alliance and Merck. Jeff is currently the CEO of Real Endpoints, a leader in providing insights, support and tools to strengthen access to pharmaceutical and digital health innovation for an evolving healthcare landscape with a concentrated focus on value based arrangements, patient services and market access support for biopharma manufacturers and payors. Jeff is also a Senior Advisor to the private equity firm Permira and serves as Chairman of Valeris, a portfolio company focused on patient support services. Prior to Real Endpoints, Jeff served as an Executive Vice President of UnitedHealth Group/Optum where he led Optum’s London-based International division, as CEO while also driving key strategic initiatives within Optum’s pharmacy benefits management division, OptumRx. Prior to joining UnitedHealth Group/Optum, Jeff was a member of the Executive Committee of the Walgreens Boots Alliance where he served as President of Pharma and Global Market Access. In this role, Berkowitz was responsible for generic and branded procurement, inventory management, relationships with pharmaceutical companies as well as the companies pricing and reimbursement strategies with all payors and payor segments. Jeff also led Walgreens specialty pharmacy business with over $10 billion in revenue and 5,800 employees. Before the formation of the Walgreens Boots Alliance, Jeff served as President of Walgreens Boots Alliance Development GmbH, where he was based in Bern, Switzerland for three years, with responsibility for the creation and development of a new joint venture company overseeing relationships with branded and generic pharmaceutical manufacturers. As the senior-most Walgreens executive residing outside of the U.S., Berkowitz led the global health and wellbeing efforts on the ground overseas. Prior to that, Berkowitz served as Walgreens Senior Vice President, Pharmaceutical Development and Market Access and was responsible for all pharmaceutical procurement, inventory management, managed care sales, network contracting and reimbursement. Before joining Walgreens in 2010, Jeff was senior vice president of global market access for Merck & Company, Inc. where he was accountable for all activity related to access, pricing, payer marketing, health outcomes and health technology assessments worldwide and a member of the Global Human Health and Emerging Markets leadership teams. From 2002 to 2009, Berkowitz held a variety of positions with increasing responsibility in market access, sales and marketing with Schering-Plough prior to its acquisition by Merck in 2009. His tenure there culminated in his role as group vice president of diversified products and global market access. In this capacity, he held global P&L responsibility for the company’s $2.5 billion diversified products franchises and was a member of the global management team. As a trained lawyer who practiced for a decade, he also served as legal director for Schering-Plough’s managed care and commercial group from 1998 to 2002. Before joining Schering-Plough, Berkowitz was a health care attorney for the international law firm Proskauer LLP in New York and Washington, D.C. Berkowitz serves on the board of directors of several publicly traded healthcare companies including Lundbeck A/S and Zealand Pharmaceuticals. He also served as the Chairman of privately held PharmaTwoB and as a Board Member of the privately held prescription digital therapeutics company, Click Therapeutics. Berkowitz previously served on the Board of Directors of the Swiss-American Chamber of Commerce, Infinity Pharmaceuticals, Uniphar and Esperion. He has been recognized three times in the Top 100 Most Inspiring in the Life Sciences by PharmaVoice Magazine and serves on the Editorial Advisory Boards of Life Science Leader and Pharmaceutical Commerce magazines.

Meenakshi Datta

Sidley Austin LLP, Partner, Healthcare, Crisis Management and Strategic Response, Privacy and Cybersecurity

Meena Datta is global co-leader of the Sidley’s Healthcare practice and a member of the global Life Sciences team. She manages key strategic matters for life sciences and healthcare companies throughout the world, particularly drug pricing and market access and patient access strategy in the MFN policy landscape. She was a key lawyer on the Sidley team that defeated MFN 1 on behalf of BIO. California Life Scis. Assn. v. CMS, 2020 WL 7696050 (N.D. Cal. 2020). Clients value Meena for her problem-solving and creativity while giving measured guidance to appropriately manage and reduce risk.

Richard Francis

President and Chief Executive Officer, Member of the Board of Directors, Teva Pharmaceutical Industries

As Chief Executive Officer, Richard Francis is leading Teva to a new strategic path for growth by driving great science from the clinic to the patient to provide life-changing medications around the world. Mr. Francis assumes the role of Teva CEO with a compelling track record of growing businesses in the life sciences, biologics and generic drug sectors and is known for his entrepreneurial and pragmatic leadership style. He is passionate about people and culture and has a reputation for building talented teams that achieve remarkable results. Mr. Francis brings over two and a half decades of experience to his position, including five years as the Chief Executive Officer of Sandoz and a member of the Novartis Executive Team. Prior to that, Mr. Francis also spent 13 years as a senior executive at Biogen where he held multiple global assignments and rose through the ranks to become President, SVP, of the U.S. business, leading the company through multiple successful commercial launches, including Tecfidera® to treat relapsing multiple sclerosis in 2013. Mr. Francis has deep experience bringing to market best in-class-therapeutics, innovative medicines and complex generics. As an avid sports fan, Mr. Francis understands the importance of taking a team approach to drive impactful growth. Mr. Franics has a demonstrated history of delivering sustained business success and leading cultural change in the pharmaceuticals industry. He holds a Bachelor of Arts in Economics from The Manchester Metropolitan University.

Richard Girling

Partner, Centerview Partners

Mr. Girling established the European business of Centerview Partners in London in 2009 and co-founded the Life Sciences practice. The Centerview Partners Healthcare team has advised on a number of significant transactions including: AstraZeneca on the $119bn defence from Pfizer, Walgreens Boots Alliance on the $6.5bn sale of its Alliance Healthcare businesses to AmerisourceBergen, Teva on its TL1A partnership transaction with Sanofi, CSL on its acquisition of Aventis Behring and its acquisition of Novartis’ influenza vaccines business, Hikma on its acquisition of Boehringer Ingelheim’s Roxane Laboratories, Galenica on its $2bn IPO of Galenica Santé and separation of Vifor Pharma, Sanofi on its $1.9bn acquisition of Kadmon and up to $1.1bn sale of Enjaymo to Recordati, Takeda on its acquisition of TiGenix and Arvelle Therapeutics on its $960mm sale to Angelini Pharma. Recently Mr. Girling has advised Zealand Pharma on its up to $5.3bn collaboration and licensing agreement with Roche, EsoBiotec on its up to $1bn sale to AstraZeneca and WBA on its $23.7bn sale to Sycamore Partners. Mr. Girling established Merrill Lynch’s European healthcare practice in 1998, and was Global Co Head of Healthcare investment banking for the last six of those years. Following the acquisition by Bank of America, he was appointed the head of the merged Europe, Middle East and Asia (EMEA) and Asia-Pacific healthcare practices for the combined organization. Mr. Girling joined Merrill Lynch in 1998 from Salomon Brothers, where he worked from 1989 to 1998 and was head of the European Pharmaceutical and Healthcare team. Mr. Girling is an Honorary Fellow of St Anne‘s College, Oxford University and a member of the Executive Advisory Board for the Centre for Personalised Medicine at Oxford University. Mr. Girling holds a B.A. and M.A. degrees in Biochemistry from Oxford University.

William H. Lewis, J.D., MBA

Chair and Chief Executive Officer Insmed

Will joined Insmed in 2012 as President and Chief Executive Officer and as a member of the board of directors. He became Chair of the Board of Directors in November 2018. Will is the former Co-Founder, President, and Chief Financial Officer of Aegerion Pharmaceuticals, Inc. (Nasdaq: AEGR), and previously spent more than 10 years working in investment banking in the U.S. and Europe. He also previously worked for the U.S. government. Will holds a Bachelor of Arts degree cum laude from Oberlin College as well as a Master of Business Administration and a Juris Doctor with Honors from Case Western Reserve University. Will is the Chair of the board of directors of NewAmsterdam Pharma (Nasdaq: NAMS).

Dr Moncef Slaoui

Chairman Cureva Vaccine

Dr Moncef Slaoui, a Moroccan Belgian and American scientist, holds a PhD in Immunology. He spent a long career in vaccine and medicine research and development during which he was involved in the development of several vaccines including the first ever vaccine against Malaria. In 2020 he was the Chief Scientific Advisor to Operation Warp Speed. Under his leadership the Operation enabled the fastest ever development manufacturing and approval of COVID19 vaccines.

He was Chairman of R&D at GSK where his career spanned almost 30 years. After retiring from GSK in 2017, he joined Medicxi ventures and since remained a dynamic force in life sciences, serving on the boards of several Biotechnology companies including Moderna and Vaxcyte (2017-2020). He currently chairs the boards of Altesa Arcturus and Curevo.

In 2016, Dr Slaoui was recognized as one of Fortune's 50 Greatest World Leaders for his work in under-researched diseases common in the developing world.

CONFERENCE LOCATION

Park Hyatt Zurich

Beethovenstrasse 21, Zürich
8002 Zürich

Park Hyatt Zurich is perfectly situated between the picturesque Lake Zurich and the famous Old Town. Indulge in the finest elements of the Swiss commitment to serenity, luxury and art. Enjoy culinary delights, first-class service and all that Zurich has to offer, right from your doorstep.

MONDAY DINNER

AURA Banquet Hall

Bleicherweg 5, Zürich
8001 Zürich

SUNDAY DINNER

Restaurant Seerose

Seestrasse 493, Zürich
8038 Zürich

REGISTRATION